Acrux Limited
Acrux Limited, together with its subsidiaries, develops and commercializes generic and topically applied pharmaceutical products in Australia, Europe, the United States, and internationally. The company provides estradiol transdermal sprays to women for the treatment of flushes associated with menopause under the Evamist and Lenzetto brand names; Dapsone 5% and Dapsone 7.5%, which are gels for th… Read more
Acrux Limited (ARUXF) - Total Liabilities
Latest total liabilities as of June 2025: $6.20 Million USD
Based on the latest financial reports, Acrux Limited (ARUXF) has total liabilities worth $6.20 Million USD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Acrux Limited - Total Liabilities Trend (2002–2025)
This chart illustrates how Acrux Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Acrux Limited Competitors by Total Liabilities
The table below lists competitors of Acrux Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Semilux International Ltd. Ordinary Shares
NASDAQ:SELX
|
USA | $165.48 Million |
|
Stenocare AS
CO:STENO
|
Denmark | Dkr3.09 Million |
|
VIOL Co. Ltd
KQ:335890
|
Korea | ₩5.60 Billion |
|
Marvel Biosciences Corp.
PINK:MBCOF
|
USA | $4.33 Million |
|
Neurobo Pharmaceuticals Inc
NASDAQ:NRBO
|
USA | $9.19 Million |
|
Synertec Corporation Ltd
AU:SOP
|
Australia | AU$12.07 Million |
|
Digicontent Limited
NSE:DGCONTENT
|
India | ₹2.01 Billion |
Liability Composition Analysis (2002–2025)
This chart breaks down Acrux Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.07 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 6.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.86 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Acrux Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Acrux Limited (2002–2025)
The table below shows the annual total liabilities of Acrux Limited from 2002 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | $6.20 Million | +9.06% |
| 2024-06-30 | $5.69 Million | +23.93% |
| 2023-06-30 | $4.59 Million | -11.95% |
| 2022-06-30 | $5.21 Million | +7.33% |
| 2021-06-30 | $4.86 Million | -2.63% |
| 2020-06-30 | $4.99 Million | +99.72% |
| 2019-06-30 | $2.50 Million | -0.87% |
| 2018-06-30 | $2.52 Million | -25.50% |
| 2017-06-30 | $3.38 Million | -64.34% |
| 2016-06-30 | $9.48 Million | +20.48% |
| 2015-06-30 | $7.87 Million | -29.51% |
| 2014-06-30 | $11.16 Million | +81.76% |
| 2013-06-30 | $6.14 Million | +13.83% |
| 2012-06-30 | $5.40 Million | -59.38% |
| 2011-06-30 | $13.28 Million | +323.57% |
| 2010-06-30 | $3.14 Million | -15.86% |
| 2009-06-30 | $3.73 Million | +18.02% |
| 2008-06-30 | $3.16 Million | +48.75% |
| 2007-06-30 | $2.12 Million | -19.92% |
| 2006-06-30 | $2.65 Million | +64.47% |
| 2005-06-30 | $1.61 Million | +19.52% |
| 2004-06-30 | $1.35 Million | +14.18% |
| 2003-06-30 | $1.18 Million | +35.69% |
| 2002-06-30 | $870.46K | -- |